Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Spaak J) "

Sökning: WFRF:(Spaak J)

Sortera/gruppera träfflistan
  • Edfors, R., et al. (författare)
  • Use of proteomics to identify biomarkers associated with chronic kidney disease and long-term outcomes in patients with myocardial infarction
  • 2020
  • Ingår i: Journal of Internal Medicine. - : Wiley-Blackwell. - 0954-6820 .- 1365-2796. ; 288:5, s. 581-592
  • Tidskriftsartikel (refereegranskat)abstract
    • Background: Patients with chronic kidney disease (CKD) have poor outcomes following myocardial infarction (MI). We performed an untargeted examination of 175 biomarkers to identify those with the strongest association with CKD and to examine the association of those biomarkers with long-term outcomes. Methods: A total of 175 different biomarkers from MI patients enrolled in the Swedish Web-System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies (SWEDEHEART) registry were analysed either by a multiple reaction monitoring mass spectrometry assay or by a multiplex assay (proximity extension assay). Random forests statistical models were used to assess the predictor importance of biomarkers, CKD and outcomes. Results: A total of 1098 MI patients with a median estimated glomerular filtration rate of 85 mL min−1/1.73 m2 were followed for a median of 3.2 years. The random forests analyses, without and with adjustment for differences in demography, comorbidities and severity of disease, identified six biomarkers (adrenomedullin, TNF receptor-1, adipocyte fatty acid-binding protein-4, TNF-related apoptosis-inducing ligand receptor 2, growth differentiation factor-15 and TNF receptor-2) to be strongly associated with CKD. All six biomarkers were also amongst the 15 strongest predictors for death, and four of them were amongst the strongest predictors of subsequent MI and heart failure hospitalization. Conclusion: In patients with MI, a proteomic approach could identify six biomarkers that best predicted CKD. These biomarkers were also amongst the most important predictors of long-term outcomes. Thus, these biomarkers indicate underlying mechanisms that may contribute to the poor prognosis seen in patients with MI and CKD.
  • Mohammad, M. A., et al. (författare)
  • Intravenous beta-blocker therapy in ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention is not associated with benefit regarding short-term mortality: a Swedish nationwide observational study
  • 2017
  • Ingår i: Eurointervention. - : Europa Edition. - 1774-024X .- 1969-6213. ; 13:2, s. E210-E218
  • Tidskriftsartikel (refereegranskat)abstract
    • Aims: Our aim was to investigate the impact of intravenous (IV) beta-blocker therapy on short-term mortality and other in-hospital events in patients with ST-segment elevation myocardial infarction (STEMI) treated with dual antiplatelet therapy (DAPT) and primary percutaneous coronary intervention (PCI). Methods and results: Using the nationwide Swedish Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies (SWEDEHEART) registry, we identified all patients with STEMI undergoing PCI between 2006 and 2013. Patients with cardiogenic shock and cardiac arrest at presentation were excluded. The primary endpoint was mortality within 30 days. Secondary endpoints were in-hospital events (mortality, cardiogenic shock and left ventricular ejection fraction [LVEF] <40% at discharge). We adjusted for confounders with a multivariable model and propensity score matching. Out of 16,909 patients, 2,876 (17.0%) were treated with an IV beta-blocker. After adjusting for confounders, the IV beta-blocker group had higher 30-day all-cause mortality (HR: 1.44, 95% CI: 1.14-1.83), more in-hospital cardiogenic shock (OR: 1.53, 95% CI: 1.09-2.16) and were more often discharged with an LVEF <40% (OR: 1.70, 95% CI: 1.51-1.92). Conclusions: In this large nationwide observational study, the use of IV beta-blockers in patients with STEMI treated with primary PCI was associated with higher short-term mortality, lower LVEF at discharge, as well as a higher risk of in-hospital cardiogenic shock.
  • Edfors, Robert, et al. (författare)
  • SWEDEHEART-1-year data show no benefit of newer generation drug-eluting stents over bare-metal stents in patients with severe kidney dysfunction following percutaneous coronary intervention
  • 2020
  • Ingår i: Coronary Artery Disease. - : LIPPINCOTT WILLIAMS & WILKINS. - 0954-6928 .- 1473-5830. ; 31:1, s. 49-58
  • Tidskriftsartikel (refereegranskat)abstract
    • Background We hypothesized that the transition from bare-metal stents (BMS) to newer generation drug-eluting stents (n-DES) in clinical practice may have reduced the risk also in patients with kidney dysfunction. Methods: Observational study in the national SWEDEHEART registry, that compared the 1-year risk of in-stent restenosis (RS) and stent thrombosis (ST) in all percutaneous coronary intervention treated patients(n = 92 994) during 2007-2013. Results: N-DES patients were younger than BMS, but had more often diabetes, previous myocardial infarction, previous revascularization and were more often treated with potent platelet inhibition. N-DES versus BMS, was associated with lower 1-year risk of RS in patients with estimated glomerular filtration rate (eGFR) >60 with a cumulative probability of 2.1% versus 5.3%, adjusted hazard ratio 0.30, 95% CI (0.27-0.34) and with eGFR 30-60: 3.0% versus 4.9%; hazard ratio 0.46 (0.36-0.60) but not in patients with eGFR <30: 8.1% versus 6.0%; hazard ratio 1.32 (0.71-2.45) (pinteraction = 0.009) as well as lower risk of ST for eGFR >60 and eGFR 30-60: 0.5% versus 0.9%; hazard ratio 0.52 (0.40-0.68) and 0.6% versus 1.3%; hazard ratio 0.54 (0.54-0.72) but not for eGFR <30; 2.1% versus 1.1%; hazard ratio 1.49 (0.56-3.98) (p(interaction)= 0.027). Conclusion: N-DES is associated with lower 1-year risk of in-stent restenosis and stent thrombosis in patients with normal or moderately reduced kidney function but not in patients with severe kidney dysfunction, where stenting is associated with worse outcomes regardless of stent type.
Skapa referenser, mejla, bekava och länka
Typ av publikation
tidskriftsartikel (92)
konferensbidrag (23)
forskningsöversikt (1)
Typ av innehåll
refereegranskat (88)
övrigt vetenskapligt (28)
Spaak, J (109)
Jernberg, T (47)
Spaak, Jonas (26)
Evans, M. (25)
Szummer, K. (24)
Hofman-Bang, C (21)
visa fler...
Jernberg, Tomas (17)
Erlinge, D. (17)
Carrero, JJ (16)
Kahan, T (15)
Jacobson, SH (15)
Lindhagen, L (15)
Edfors, R (15)
Tornvall, P (14)
Lindhagen, Lars (13)
Persson, H (12)
James, S. (11)
Norberg-Spaak, Lena (11)
Lindahl, B (11)
Andell, P (11)
Szummer, Karolina (10)
Evans, Marie (10)
Carrero, Juan-Jesus (10)
Sorensson, P (9)
Agewall, S (9)
Daniel, M. (9)
Henareh, L (9)
Ekenback, C (9)
Collste, O (9)
Fåhraeus, Robin (9)
Coates, Philip J (9)
Nylander, Karin (9)
Baron, T (9)
Linnarsson, D (8)
Boldrup, Linda (8)
Y-Hassan, S (8)
Erlinge, David (7)
Caidahl, K (7)
Koul, S (7)
Marko-Varga, G (7)
Lagerqvist, B. (7)
Wilms, Torben (7)
Sgaramella, Nicola (7)
Rezeli, M (7)
Sundblad, P (7)
Malmqvist, K (6)
Frick, M (6)
Jensen, J. (6)
Brolin, EB (6)
Edfors, Robert (6)
visa färre...
Karolinska Institutet (87)
Uppsala universitet (23)
Umeå universitet (12)
Lunds universitet (11)
Kungliga Tekniska Högskolan (7)
Göteborgs universitet (6)
visa fler...
Linköpings universitet (3)
Mittuniversitetet (3)
Örebro universitet (2)
Stockholms universitet (1)
Högskolan Dalarna (1)
visa färre...
Engelska (115)
Svenska (1)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (44)
Samhällsvetenskap (4)
Naturvetenskap (2)


Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy